6CM
APLT

683 Capital Management’s Applied Therapeutics APLT Stock Holding History

683 Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,700
Closed -$125K – 225
2024
Q3 		$125K Buy
+14,700
New +$86.6K 0.01% 115

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

683 Capital Management's APLT Position: Q1 2024 in Review

683 Capital Management sold out of Applied Therapeutics (APLT) in Q1 2024, closing a stake of 100,806 shares — an estimated $338K sold.

683 Capital Management first reported a position in APLT in Q4 2023 and held it in 1 quarter. The position peaked at $338K in Q4 2023. 89 funds tracked by Wall St. Rank hold APLT as of Q1 2024.

  • 683 Capital Management reported no remaining Applied Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 100,806 Applied Therapeutics shares in Q1 2024, an estimated $338K.
  • 683 Capital Management first reported a position in Applied Therapeutics in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Applied Therapeutics position peaked at $338K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.